Juvederm-treatment.jpg In a recent study conducted on patients who had undergone previous nasolabial fold (NLF) treatments with Restylane (hyaluronic acid/HA, Medicis), it was seen that there was a strong preference for Juvéderm Ultra (HA, Allergan) among the patients. This study was conducted by Jessica Wu, M.D., clinical instructor of dermatology at the University of Southern California, Los Angeles.

Study Highlights
a. This was a single-center, open-label trial on 30 patients.
b. 20 patients had moderate NLFs and NLFs of the other 10 was evaluated as severe at baseline.
c. All the patients had undergone Restylane treatments for their NLFs within the previous year.
d. At the baseline, all subjects completed questionnaires about their impressions of Restylane.
e. During the study, Juvéderm injection volumes were less than or equal to total volumes of Restylane used, including Restylane touchups.
f. However, no Juvéderm touchups were allowed.
g. Again at the baseline, Juvéderm's effectiveness was evaluated at two weeks and three months post-treatment, on a 5-point scale.
h. It was seen that at two weeks, patients' mean scores declined 1.8 points versus baseline.
i. At 3 months, the difference was 1.3 points.
j. The mean volume of Juvéderm versus Restylane required was also evaluated.
k. It was seen that patients required 22 per cent less of Juvederm.
l. Mean time from previous treatment was nine months, while mean time to dissatisfaction with this treatment was 4.1 months.
m. It was noticed that 82.7 per cent admitted that Juvederm provided longer-lasting improvements than Restylane.
n. This was 3 months after treatment with Juvéderm
o. It was also noticed that, 96.6 per cent of patients felt that Juvéderm provided better overall improvement in their NLF.
p. 89.7 per cent said that Juvéderm provided a more satisfying reduction in NLF appearance.
q. Juvéderm was also seen as less painful during and after injection with less bruising, redness and swelling than Restylane.